NCPA joined the Alliance for Pharmacy Compounding, the Professional Compounding Centers of America, and Fagron North America in signing onto a letter to the Trump transition team advocating for various compounding policies. Specifically, the group advocated for compounders’ rights to compound during drug shortages, to preserve access to active pharmaceutical ingredients, and to preserve compounders’ ability to compound animal drugs, among other issues.
NCPA
